The LGEHD laboratory was established in July 2020. The major topic of the Laboratory research is genetic and epigenetic control on immune response regulating molecules in disease development, progression and treatment (with special focus on the pathogenic role of immune checkpoints molecules in human diseases). In particular, our studies concentrate on:
- investigation of inherited variations within genes regulating the immune response in relation to the risk of developing cancer, autoimmune and other diseases;
- evaluation of the relationship between epigenetic modifications (e.g. DNA methylation and microRNA) and the risk of disease development and progression;
- searching for biomarkers of response to immunotherapeutic treatment;
- examination of the functional relevance of inherited genetic variants.
Currently, 2 research grants are being carried out in the Laboratory:
- Grant OPUS 17 financed by the National Science Centre: “The immune checkpoints in non-small cell lung cancer-research on genetic and epigenetic mechanism regulating mRNA and protein expression” principal investigator: Monika Jasek MSc, PhD, DSc; 2 257 528 PLN (2020-2023) (grant No. 2019/33/B/NZ5/03029)
- Project financed by the Hr. Potocki Foundation: “The influence of genetic variations in genes coding PD-1/PD-L1 on the risk of kidney cancer and the course of disease” principal investigator: Lidia Karabon MSc, PhD, DSc 95 000 PLN (2020-2021)